Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix-IPV Versus a Licensed Men-C Vaccine With Pediacel When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months

Trial Profile

Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix-IPV Versus a Licensed Men-C Vaccine With Pediacel When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2014

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; DTaP poliovirus vaccine; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Neisseria infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Nov 2008 Primary endpoint 'Antibody levels' has been met.
    • 01 Nov 2008 Primary endpoint 'Seroprotection rate' has been met.
    • 01 Nov 2008 Results published in Archives of Disease in Childhood, according to 1124825.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top